Literature DB >> 12495304

Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

Steven Coca1, Mark A Perazella.   

Abstract

Drug-induced renal failure is a relatively common event in patients infected with HIV. This group of patients receives a number of potentially nephrotoxic medications for a variety of illnesses. The acyclic nucleoside phosphonates cidofovir and adefovir are antivirals that possess significant nephrotoxicity. Interestingly, tenofovir disoproxil fumurate (DF) is structurally similar to these 2 agents, yet seems to be less nephrotoxic based on a few published studies in HIV patients with intact renal function. We present a case in which acute renal failure developed after therapy with tenofovir DF in a patient with HIV and stable chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495304     DOI: 10.1097/00000441-200212000-00011

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  33 in total

1.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

2.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.

Authors:  Christina M Wyatt; Carlos Malvestutto; Steven G Coca; Paul E Klotman; Chirag R Parikh
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

4.  Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors.

Authors:  Warren A Andiman; Miriam C Chernoff; Charles Mitchell; Murli Purswani; James Oleske; Paige L Williams; Hans Spiegel; Phil Gona; George R Seage
Journal:  Pediatr Infect Dis J       Date:  2009-07       Impact factor: 2.129

5.  Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.

Authors:  Mohamad Zaidan; François-Xavier Lescure; Isabelle Brochériou; Sarah Dettwiler; Jean-Baptiste Guiard-Schmid; Jérôme Pacanowski; Eric Rondeau; Gilles Pialoux; Pierre-Marie Girard; Pierre Ronco; Emmanuelle Plaisier
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 8.237

6.  Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.

Authors:  Kyle E Giesler; Jose Marengo; Dennis C Liotta
Journal:  J Med Chem       Date:  2016-07-22       Impact factor: 7.446

Review 7.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.

Authors:  Koen K A Van Rompay; Laurie L Brignolo; Dennis J Meyer; Christopher Jerome; Ross Tarara; Abigail Spinner; Marta Hamilton; Linda L Hirst; David R Bennett; Don R Canfield; Trish G Dearman; Wilhelm Von Morgenland; Phil C Allen; Celia Valverde; Alesha B Castillo; R Bruce Martin; Valerie F Samii; Ray Bendele; John Desjardins; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 9.  Tenofovir disoproxil fumarate.

Authors:  Therese Chapman; Jane McGavin; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.

Authors:  Douglas T Dieterich
Journal:  J Int AIDS Soc       Date:  2006-01-19       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.